• Medientyp: E-Artikel
  • Titel: Abstract W P379: Pre-treatment with Selective Serotonin Reuptake Inhibitors is Associated with Improved Short-term Outcome in Acute Ischemic Stroke
  • Beteiligte: Siepmann, Timo; Kepplinger, Jessica; Zerna, Charlotte; Penzlin, Ana Isabel; Reichmann, Heinz; Pallesen, Lars-Peder; Puetz, Volker; Bodechtel, Ulf; Barlinn, Kristian
  • Erschienen: Ovid Technologies (Wolters Kluwer Health), 2015
  • Erschienen in: Stroke
  • Sprache: Englisch
  • DOI: 10.1161/str.46.suppl_1.wp379
  • ISSN: 0039-2499; 1524-4628
  • Schlagwörter: Advanced and Specialized Nursing ; Cardiology and Cardiovascular Medicine ; Neurology (clinical)
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p> <jats:bold>Background and Purpose:</jats:bold> Treatment with Selective Serotonin Reuptake Inhibitors (SSRIs) following acute ischemic stroke was shown to improve functional and motor recovery independently of depression, possibly mediated by long-term mechanisms such as increased brain plasticity. In animal studies, chronic SSRI treatment is superior over short-term SSRI in evoking neurogenesis but the applicability of this observation to humans remains unelucidated. We hypothesized that pre-treatment with SSRI in acute ischemic stroke patients is associated with improved recovery compared to post-stroke SSRI. </jats:p> <jats:p> <jats:bold>Subjects and Methods:</jats:bold> We performed an exploratory analysis in consecutive acute ischemic stroke patients who were pre-treated or treated de novo either with fluoxetine, citalopram or escitalopram. Effects of SSRI-pre-treatment on short-term clinical (total NIHSS and NIHSS motor items) and functional (mRS) outcome at discharge compared to post-stroke SSRI were assessed using bivariate and multivariate analyses. </jats:p> <jats:p> <jats:bold>Results:</jats:bold> Of 2653 patients screened, 239 were included (aged 69±14 years, mean±SD; 42% men, baseline median NIHSS 7 [IQR, 10]). Compared to post-stroke SSRI (n=188), in the SSRI pre-treatment group (n=51) favorable functional outcome at discharge (mRS≤2) was more frequent (41% vs. 20%; p=0.002), duration of hospitalization was shorter (median: 7 versus 11 days; p&lt;0.0001), and there was a non-significant trend toward improved motor recovery (decrease in NIHSS motor items ≥2 points or 0-1 at discharge; 63% vs. 49%; p=0.08). However there was no such difference in total NIHSS recovery (≥4 points or 0-1 at discharge; p=n.s.). Pre-treatment with SSRI was an independent predictor of favorable functional outcome (mRS≤2) at discharge (OR: 4.00; 95%CI: 1.68-9.57; p=0.002) after adjusting for age, pre-stroke mRS, baseline NIHSS and IV-thrombolysis. </jats:p> <jats:p> <jats:bold>Conclusions:</jats:bold> Our data suggest that pre-treatment with SSRI may be linked to early clinical recovery after acute ischemic stroke and support the hypothesis that pre-stroke SSRI might be superior to post-stroke SSRI. </jats:p>
  • Zugangsstatus: Freier Zugang